Wet Age-Related Macular Degeneration Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies, NICE Approvals, Prevalence, and Companies by DelveInsight

Wet Age-Related Macular Degeneration Treatment Market

(Albany, USA) DelveInsight’s “Wet Age-Related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of the Wet Age-Related Macular Degeneration, historical and forecasted epidemiology as well as the Wet Age-Related Macular Degeneration market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Wet Age-Related Macular Degeneration market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Wet Age-Related Macular Degeneration market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Wet Age-Related Macular Degeneration treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Wet Age-Related Macular Degeneration market.

Discover which therapies are expected to grab the Wet Age-Related Macular Degeneration Market Share @ Wet Age-Related Macular Degeneration Market Outlook

Key Takeaways from the Wet Age-Related Macular Degeneration Market Report

• In April 2025, Kodiak Sciences Inc. announced phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
• In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) in the 7MM were nearly 40 million in 2023.
• The highest total diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) were accounted by the US in 2023 (~14 million), which are expected to show a rise in the future.
• Among the European countries, Germany had the highest diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) with ~6 million cases in 2023. On the other hand, Spain had the lowest prevalent population (~2 million cases).
• Japan had nearly 8 million total diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) in 2023, accounting for approximately 21% in 7MM.
• Based on age-specific segmentation, the people in the age group of 70-79 were affected the most by Wet Age-Related Macular Degeneration (Wet AMD) in the US, accounting for approximately 406 thousand cases in 2023.
• The DelveInsight analysis indicates that in Japan, there are more number of cases of people with Dry AMD than people with Wet AMD, with approximately 90% of total cases and 10% of cases in 2023.
• Among the European countries, Germany had the highest diagnosed prevalent cases of Wet AMD with ~595 thousand cases, followed by France, which had prevalent population of ~389 thousand in 2023. On the other hand, Spain had the lowest prevalent population (~160 thousand cases).
• Japan had ~840 thousand total diagnosed prevalent cases of Wet Age-Related Macular Degeneration (Wet AMD) in 2023, accounting for approximately 21% in 7MM.
• In 2023, in the US, the age-specific diagnosed prevalent cases of Wet AMD were highest for age group 70-79 (~407 thousand), followed by 60-69 (~393 thousand), =80 (~304 thousand), and 50-59 (~252 thousand).
• The increase in Wet Age-Related Macular Degeneration Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Wet Age-Related Macular Degeneration Market is anticipated to witness growth at a considerable CAGR.
• The leading Wet Age-Related Macular Degeneration Companies such as Opthea Limited, Outlook Therapeutics, Kodiak Sciences, Regenxbio, Dobecure, Gemini Therapeutics, Huabo Biopharm, Isarna Therapeutics, IVERIC bio (formerly Ophthotech Corporation), Ribomic, Curacle, Bio-Thera Solutions, AngioLab Inc, Alkahest, Tyrogenex, Iconic Therapeutics, AiViva BioPharma, Boehringer Ingelheim, RemeGen, and others.
• Promising Wet Age-Related Macular Degeneration Pipeline Therapies such as RGX-314, Tarcocimab tedromer, Aflibercept, KSI-301, Eyp-1901, ALK4290, and others.

Wet Age-Related Macular Degeneration Epidemiology Segmentation in the 7MM

The epidemiology section of Wet Age-Related Macular Degeneration offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

Download the report to understand which factors are driving Wet Age-Related Macular Degeneration Epidemiology trends @ Wet Age-Related Macular Degeneration Prevalence

Wet Age-Related Macular Degeneration Marketed Drugs

• BEOVU (Brolucizumab): Novartis

BEOVU (Brolucizumab), developed by Novartis, is a potent anti-VEGF treatment used for Wet Age-Related Macular Degeneration (Wet-AMD). It works by inhibiting vascular endothelial growth factor, reducing abnormal blood vessel growth and fluid leakage in the retina. BEOVU offers a longer dosing interval, allowing up to 12-week dosing schedules.

• EYLEA (aflibercept): Regeneron Pharmaceuticals

EYLEA, developed by Regeneron, is used to treat wet age-related macular degeneration (wet-AMD), diabetic eye disease, and other retinal issues. The drug, aflibercept, is an injectable treatment that slows vision loss by blocking abnormal blood vessel growth in the eye. EYLEA works as a soluble decoy receptor, inhibiting VEGF-A and PlGF to prevent abnormal blood vessel formation. The standard dosage is 2 mg every 4 weeks for the first 3 months, then every 8 weeks. Regeneron is currently testing less frequent dosing and higher doses in ongoing phase III trials.

• VABYSMO (faricimab): Roche/ Genentech, Inc.

VABYSMO (faricimab) is the first bispecific antibody designed for the eye. It targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralizing angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Ang-2 and VEGF-A contribute to vision loss by destabilizing blood vessels, causing new leaky blood vessels to form and increasing inflammation. By blocking both pathways involving Ang-2 and VEGF-A, VABYSMO is designed to stabilize blood vessels.

Stay ahead in the Wet Age-Related Macular Degeneration Therapeutics Market with DelveInsight’s Strategic Report @ Wet Age-Related Macular Degeneration Market Outlook

Wet Age-Related Macular Degeneration Emerging Drugs

• OPT-302: Opthea Limited

OPT-302 (sVEGFR-3) is the first ‘Trap’ inhibitor of VEGF-C and VEGF-D designed specifically for the eye. OPT-302 blocks the two members of the VEGF family which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases, including wet AMD and DME. In combination with anti-VEGF-A therapies, OPT-302 completely shuts-down VEGFR-2 and VEGFR-3 activity and targets mechanisms of resistance and suboptimal clinical response to existing therapies.

• KSI-501: Kodiak Sciences Inc.

KSI-501 is a novel anti-VEGF biologic designed to rapidly inhibit VEGF and provide extended durability of action to reduce the burden of frequent anti-VEGF injections. Delivering potent and sustained VEGF inhibition enables patient compliance, results in long-term efficacy, and improves visual acuity outcomes.

Wet Age-Related Macular Degeneration Market Outlook

Wet Age-Related Macular Degeneration (wet AMD) is a progressive eye condition characterized by the growth of abnormal blood vessels beneath the retina, which can lead to severe vision loss. Treatment aims to manage symptoms, slow disease progression, and preserve vision. The primary therapeutic approach for wet AMD is anti-vascular endothelial growth factor (anti-VEGF) therapy. These medications, including ranibizumab (LUCENTIS), aflibercept (EYLEA), and brolucizumab (BEOVU), work by inhibiting VEGF, a protein that promotes the growth of abnormal blood vessels. Administered via intravitreal injections, these drugs reduce fluid leakage and vascular growth, stabilizing or improving vision in many patients.

The Wet Age-Related Macular Degeneration (wAMD) market is driven by several key factors, including the rising prevalence of the disease due to an aging global population, increased awareness and early diagnosis, and ongoing advancements in treatment options such as anti-VEGF therapies and emerging gene therapies. Additionally, robust research pipelines, growing healthcare expenditure, and supportive government initiatives further contribute to market growth. However, the market also faces notable barriers, such as the high cost of treatment, limited accessibility in low-income regions, the need for frequent intravitreal injections, and challenges in achieving long-term efficacy and patient adherence. Moreover, competition among therapeutic alternatives and the complex nature of drug development for retinal diseases can also hinder market expansion.

Learn more about the FDA-approved drugs for Wet Age-Related Macular Degeneration @ Drugs for Wet Age-Related Macular Degeneration Treatment

Wet Age-Related Macular Degeneration Drugs Uptake

The drug chapter of the Wet Age-Related Macular Degeneration report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Wet Age-Related Macular Degeneration.

Major Wet Age-Related Macular Degeneration Companies are Opthea Limited (ASX: OPT), Outlook Therapeutics (NASDAQ: OTLK), Kodiak Sciences (NASDAQ: KOD), Regenxbio (NASDAQ: RGNX), Dobecure (Private), Gemini Therapeutics (NASDAQ: GMTX), Huabo Biopharm (Private), Isarna Therapeutics (Private), IVERIC bio (NASDAQ: ISEE), Ribomic (TYO: 4591), Curacle (KOSDAQ: 301300), Bio-Thera Solutions (SHA: 688177), AngioLab Inc. (KOSDAQ: 251280), Alkahest (Acquired by Grifols – BME: GRF), Tyrogenex (Private), Iconic Therapeutics (Private), AiViva BioPharma (Private), Boehringer Ingelheim (Private), RemeGen (HKEX: 9995, SHA: 688331), and others

Scope of the Wet Age-Related Macular Degeneration Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Wet Age-Related Macular Degeneration Companies- Opthea Limited, Outlook Therapeutics, Kodiak Sciences, Regenxbio, Dobecure, Gemini Therapeutics, Huabo Biopharm, Isarna Therapeutics, IVERIC bio (formerly Ophthotech Corporation), Ribomic, Curacle, Bio-Thera Solutions, AngioLab Inc, Alkahest, Tyrogenex, Iconic Therapeutics, AiViva BioPharma, Boehringer Ingelheim, RemeGen, and others.
• Wet Age-Related Macular Degeneration Pipeline Therapies- RGX-314, Tarcocimab tedromer, Aflibercept, KSI-301, Eyp-1901, ALK4290, and others.
• Wet Age-Related Macular Degeneration Market Dynamics: Wet Age-Related Macular Degeneration Market Drivers and Barriers
• Wet Age-Related Macular Degeneration Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Wet Age-Related Macular Degeneration Drugs in development @ Wet Age-Related Macular Degeneration Clinical Trials Assessment and FDA Approvals

Table of Content

1 Key Insights

2 Report Introduction

3 Wet AMD Market Overview at a Glance

4 Wet AMD Market: Future Perspective

5 Executive Summary

6 Key Events

7 Disease Background and Overview

8 Epidemiology and Patient Population

9 Patient Journey

10 Marketed Drugs

11 Emerging Drugs of Wet AMD

12 Wet AMD: Market Analysis

13 Key Opinion Leaders’ Views

14 SWOT Analysis

15 Unmet Needs

16 Market Access and Reimbursement

17 Appendix

18 DelveInsight Capabilities

19 Disclaimer

About DelveInsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services